LLPC geassocieerde studies

Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B)

previously untreated MCL, high risk. At least one High risk MCL feature, defined as I. MIPI-c high intermediate (HI) or high (H) risk (i.e. high-risk MIPI irrespective of Ki-67 or intermediate risk MIPI and Ki-67>=30% (Ki-67 based on local pathology) 
and/or 
II. TP53 deletion and /or mutation and/or TP53 overexpression by immunohistochemistry (> 50% of lymphoma cells), sequencing (mutations and deletions) or FISH

Huidige fase 1 a/b cohorten zijn open;

• Expansie Cohort C: voor frontline LBCL - Dose Level 3: 2.0 x 105 KITE-753 CAR+ T cells/kg
• Expansie Cohort D: voor R/R MCL - Dose Level 3: 2.0 x 105 KITE-753 CAR+ T cells/kg

Huidige fase 2 cohort is open;

• R/R LBCL na tenminste 2 eerdere systemische behandellijnen
• Dose Level 3: 2.0 x 105 KITE-753 CAR+ T cells/kg

Open in Amsterdam UMC, location VUMC (m.j.kersten@amsterdamumc.nl, ilse.kuipers@amsterdamumc.nl, trialbureaulymfoid@amsterdamumc.nl)

Study informatie 
Study Schema

A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton’s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies

R/R CLL/SLL with CNS involvement

In- en exclusiecriteria
Advertentie tekst (goedgekeurd door EC)